Inhibition of PD-1-mediated signaling with monoclonal antibodies has been associated with regression of several different types of solid tumors, but clinical trials of antibodies that interrupt signaling through the PD-1/PD-L1 axis in patients with CRC have to date shown limited benefit [46], [47]. This evidence concerns the gene CD274 and colorectal carcinoma.